Patient-reported outcomes with first-line cemiplimab in patients with locally advanced non-small cell lung cancer: EMPOWER-Lung 1 subpopulation

Igor Bondarenko,1* Aminet Sezer,1 Saadettin Kilickap,1,† Mahmut Gümüş,1 Mustafa Ozgöroğlu,1 Miranda Gogishvili,1 Xuanyao He,1 Giuseppe Gullo,1 Petra Rietzschl,1 Rubin GW Quek2

Department of Oncology and Medical Radiology, Diplomatov Medecinska Akademija, Dinip, Ukraine; 2Department of Medical Oncology, Başkent University, Adana, Turkey; 3Department of Medical Oncology, High Technology Medical Centre, University Clinic Lütolf, Ticino, Switzerland; 4Department of Medical Oncology, Istanbul University, Istanbul, Turkey

*Current affiliation: Department of Medical Oncology, Istanbul University, Istanbul, Turkey

The authors declare no competing interests.

Background

• The exploratory phase III EMPOWER-Lung 1 study, in patients with locally advanced non-small cell lung cancer (laNSCLC), Randomized pivotal 1:1 open-label Phase 3 (EMPOWER-Lung 1) assessed cemiplimab (CEMI, n=45) versus chemotherapy (CHEMO, n=42) in patients with laNSCLC with PD-L1 ≥50%.

Methods

• PRO assessment and scoring.
• Supplementary Appendix online as a full list of all PROs and scoring.
• Statistical analyses.

Results

• Baseline characteristics.
• Change from baseline per MMRM analysis.

Conclusion

• No statistical significant difference in overall change from baseline was observed between the two treatment arms, favouring CEMI versus CHEMO, in nausea/vomiting, dyspnoea, and appetite loss (A); statistically significant deterioration in diarrhoea; and no significant difference in any of the functioning scales in either the CEMI or the CHEMO arms.

Supplementary Figure 1

Supplementary Table 1

Supplementary Table 2

Figure 1A

Figure 1B

Figure 1C

Presentation at the 2023 European Lung Cancer Congress (ELCC), March 20–23, 2023.

*Current affiliation: Department of Medical Oncology, Istanbul University, Istanbul, Turkey

†,‡ These authors contributed equally to this work.